| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
H-Gly-Arg-Ala-Asp-Ser-Pro-OH does not have a specific biological target. It serves as a negative control peptide in studies involving fibronectin inhibitors such as GRGDdSP. The peptide is used to distinguish specific effects of RGD-containing peptides from non-specific effects.
|
|---|---|
| ln Vitro |
In vitro, H-Gly-Arg-Ala-Asp-Ser-Pro-OH is used as a negative control in cell adhesion and integrin-binding assays. It does not bind to integrins with high affinity, unlike the RGD-containing peptides it is compared against. The peptide serves as a specificity control for fibronectin inhibitor studies.
|
| ln Vivo |
In vivo, H-Gly-Arg-Ala-Asp-Ser-Pro-OH is not typically used as a therapeutic agent. It may be used as a control compound in animal studies involving fibronectin inhibitors. The peptide helps to establish the specificity of observed effects in vivo.
|
| Enzyme Assay |
Binding assays for H-Gly-Arg-Ala-Asp-Ser-Pro-OH typically involve comparing its binding to integrins or fibronectin with that of active RGD-containing peptides. Surface plasmon resonance or cell adhesion assays are used to demonstrate the lack of specific binding.
|
| Cell Assay |
Cellular assays for H-Gly-Arg-Ala-Asp-Ser-Pro-OH utilize cell adhesion and migration assays. Cells are treated with the peptide or the active RGD peptide control, and cell attachment to fibronectin-coated surfaces is measured.
|
| Animal Protocol |
In vivo studies with H-Gly-Arg-Ala-Asp-Ser-Pro-OH are conducted in rodent models as control experiments for fibronectin inhibitor studies. The peptide is typically administered via the same route as the active compound, and the absence of effect confirms specificity.
|
| ADME/Pharmacokinetics |
As a hexapeptide, H-Gly-Arg-Ala-Asp-Ser-Pro-OH is expected to have a short half-life due to proteolytic degradation. The peptide should be stored as a powder at -20degC. Standard peptide handling and storage procedures apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for H-Gly-Arg-Ala-Asp-Ser-Pro-OH are limited. The peptide is a research tool and is generally considered to have low toxicity. Standard safety precautions for laboratory handling of peptides should be followed.
|
| References | |
| Additional Infomation |
H-Gly-Arg-Ala-Asp-Ser-Pro-OH is a research-use peptide and is not approved for therapeutic applications. It is the negative control for GRGDdSP in fibronectin inhibitor studies. The peptide is used to study cell adhesion, integrin signaling, and fibronectin interactions. It is available from multiple research suppliers.
|
| Molecular Formula |
C23H39N9O10
|
|---|---|
| Molecular Weight |
601.61000
|
| Exact Mass |
601.282
|
| CAS # |
99896-86-3
|
| PubChem CID |
10393818
|
| Appearance |
White to off-white solid powder
|
| LogP |
-7.5
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
42
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN
|
| InChi Key |
YCJRGURCDKCPCI-YTFOTSKYSA-N
|
| InChi Code |
InChI=1S/C23H39N9O10/c1-11(28-19(38)12(29-16(34)9-24)4-2-6-27-23(25)26)18(37)30-13(8-17(35)36)20(39)31-14(10-33)21(40)32-7-3-5-15(32)22(41)42/h11-15,33H,2-10,24H2,1H3,(H,28,38)(H,29,34)(H,30,37)(H,31,39)(H,35,36)(H,41,42)(H4,25,26,27)/t11-,12-,13-,14-,15-/m0/s1
|
| Chemical Name |
(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~83.11 mM)
DMSO : ~50 mg/mL (~83.11 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6622 mL | 8.3110 mL | 16.6221 mL | |
| 5 mM | 0.3324 mL | 1.6622 mL | 3.3244 mL | |
| 10 mM | 0.1662 mL | 0.8311 mL | 1.6622 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
